BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37081761)

  • 21. Prognostic significance of pretreatment red blood cell distribution width in primary diffuse large B-cell lymphoma of the central nervous system for 3P medical approaches in multiple cohorts.
    Li D; Li S; Xia Z; Cao J; Zhang J; Chen B; Zhang X; Zhu W; Fang J; Liu Q; Hua W
    EPMA J; 2022 Sep; 13(3):499-517. PubMed ID: 36061828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.
    Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y
    Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma.
    Kanemasa Y; Shimoyama T; Sasaki Y; Hishima T; Omuro Y
    Ann Hematol; 2018 Jun; 97(6):999-1007. PubMed ID: 29427185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and outcomes of newly diagnosed patients with HIV-associated aggressive B-cell NHL in China.
    Wang C; Liu J; Lei H; Li Y; Wu J; Guo B; Hu R; Liu T; Wu J; Ding Y; Hu C; Liang S; Xiao C; Liang X; Huang D; Yang T; Zhang W; Yang Z; Li J; Nan Y; Li Q; Xiang Y; Li Z; Wu Y; Liu Y
    J Cell Mol Med; 2022 Oct; 26(19):5067-5077. PubMed ID: 36056692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and Validation of a Novel Risk Stratification Model for Cancer-Specific Survival in Diffuse Large B-Cell Lymphoma.
    Zhong Q; Shi Y
    Front Oncol; 2020; 10():582567. PubMed ID: 33520698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era.
    Song Z; Xu L; Tang G; Gao L; Wang L; Ni X; Chen L; Chen J; Wang T; Feng D; Yu X; Yang J; Wang Y
    Clin Chim Acta; 2022 Jul; 532():72-78. PubMed ID: 35660013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Zhou Z; Sehn LH; Rademaker AW; Gordon LI; Lacasce AS; Crosby-Thompson A; Vanderplas A; Zelenetz AD; Abel GA; Rodriguez MA; Nademanee A; Kaminski MS; Czuczman MS; Millenson M; Niland J; Gascoyne RD; Connors JM; Friedberg JW; Winter JN
    Blood; 2014 Feb; 123(6):837-42. PubMed ID: 24264230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 31. A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent.
    Procházka V; Pytlík R; Janíková A; Belada D; Sálek D; Papajík T; Campr V; Fürst T; Furstova J; Trněný M
    PLoS One; 2014; 9(7):e102594. PubMed ID: 25058337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models.
    Jelicic J; Juul-Jensen K; Bukumiric Z; Roost Clausen M; Ludvigsen Al-Mashhadi A; Pedersen RS; Poulsen CB; Brown P; El-Galaly TC; Stauffer Larsen T
    Blood Cancer J; 2023 Oct; 13(1):157. PubMed ID: 37833260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
    Ruppert AS; Dixon JG; Salles G; Wall A; Cunningham D; Poeschel V; Haioun C; Tilly H; Ghesquieres H; Ziepert M; Flament J; Flowers C; Shi Q; Schmitz N
    Blood; 2020 Jun; 135(23):2041-2048. PubMed ID: 32232482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
    J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
    Song JL; Wei XL; Zhang YK; Hao XX; Huang WM; Wei Q; Wei YQ; Feng R
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):739-744. PubMed ID: 30369184
    [No Abstract]   [Full Text] [Related]  

  • 37. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma.
    Gao R; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Yang T; Xu W
    Int J Cancer; 2018 Oct; 143(8):1884-1895. PubMed ID: 29744861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of the red blood cell distribution width in diffuse large B-cell lymphoma patients.
    Zhou S; Fang F; Chen H; Zhang W; Chen Y; Shi Y; Zheng Z; Ma Y; Tang L; Feng J; Zhang Y; Sun L; Chen Y; Liang B; Yu K; Jiang S
    Oncotarget; 2017 Jun; 8(25):40724-40731. PubMed ID: 28388534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of initial chemotherapy cycles and clinical characteristics on outcomes for HIV-associated diffuse large B cell lymphoma patients: The Central and Western China AIDS Lymphoma League 001 study (CALL-001 study).
    Wang C; Wu Y; Liu J; Min H; Huang Y; Wei G; Zhang W; Wang M; Tang X; Zhou H; Chen Y; Liu Y
    Front Immunol; 2023; 14():1153790. PubMed ID: 37063928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
    Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
    Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.